The fact
The biopharmaceutical company, focused on liver diseases, faces investor skepticism.
Analysts are watching upcoming results to assess its stability.
Click the link to read an article on the topic:
Why it matters
La volatilité de Genfit reflète les incertitudes autour des biotechs européennes, un secteur très sensible aux annonces cliniques et aux mouvements de marché.